Question

我正在尝试从以下网址的Excel中读取列：https://www.ema.europa.eu/sites/default/files/Medicines_output_european_public_assessment_reports.xlsx

我正在使用python xlrd模块读取此excel文件。我正在以dict格式逐行阅读（注意：在这里，我已经修改了小写的dict键。）

示例：（单行）

{
    'category': 'Human',
    'medicine name': 'Avastin',
    'therapeutic area': 'Carcinoma, Non-Small-Cell Lung, Breast Neoplasms, Ovarian Neoplasms, Colorectal Neoplasms, Carcinoma, Renal Cell',
    'international non-proprietary name (inn) / common name': 'bevacizumab',
    'active substance': 'bevacizumab',
    'product number': 'EMEA/H/C/000582',
    'patient safety': 'no',
    'authorisation status': 'Authorised',
    'atc code': 'L01XC07',
    'additional monitoring': 'no',
    'generic': 'no',
    'biosimilar': 'no',
    'conditional approval': 'no',
    'exceptional circumstances': 'no',
    'accelerated assessment': 'no',
    'orphan medicine': 'no',
    'marketing authorisation date': 38363.95833333334,
    'date of refusal of marketing authorisation': '',
    'marketing authorisation holder/company name': 'Roche Registration GmbH',
    'human pharmacotherapeutic group': 'Antineoplastic agents, ',
    'vet pharmacotherapeutic group': '',
    'date of opinion': '',
    'decision date': 43580.91666666666,
    'revision number': 51.0,
    'condition / indication': 'Bevacizumab in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum.Bevacizumab in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. For further information as to human epidermal growth factor receptor 2 (HER2) status.Bevacizumab in combination with capecitabine is indicated for first-line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. Patients who have received taxane and anthracycline-containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with Avastin in combination with capecitabine. For further information as to HER2 status.Bevacizumab, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology.Bevacizumab, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with Epidermal Growth Factor Receptor (EGFR) activating mutations.Bevacizumab in combination with interferon alfa-2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer.Bevacizumab, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (International Federation of Gynecology and Obstetrics (FIGO) stages III B, III C and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer.Bevacizumab, in combination with carboplatin and gemcitabine, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor–targeted agents.Bevacizumab in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor–targeted agents.Bevacizumab, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix.',
    'species': '',
    'atcvet code': '',
    'first published': 43321.43680555555,
    'revision date': 43704.375,
    'url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/avastin'
}

问题是，在excel中，我将Revision Date列设为8/27/2019 9:00:00 AM，但是在使用xlrd读取excel时，由于其列类型为43704.375，它被转换为8/27/2019 9:00:00 AM日期。

如何使用python以正确的格式读取/获取日期和时间？

为简短起见，（43704.375甚至都不是该日期的时间戳。）如何将43704.375转换为ERROR [default task-37] nmateti ActionExceptionHandler.logException(143) | java.lang.IllegalArgumentException: UT000068: Servlet path match failed at io.undertow.servlet.handlers.ServletPathMatchesData.getServletHandlerByPath(ServletPathMatchesData.java:83) at io.undertow.servlet.handlers.ServletPathMatches.getServletHandlerByPath？反之亦然？

Answer 1

Excel内部存储的日期值为浮点数。因此，在xlrd中，如果要将Excel日期值读取为Python日期值，则必须使用xldate_as_tuple方法获取日期。

文档：http://www.lexicon.net/sjmachin/xlrd.html#xlrd.xldate_as_tuple-function

这是一个通用示例：

import datetime, xlrd
book = xlrd.open_workbook("myexcelfile.xls")
sh = book.sheet_by_index(0)
a1 = sh.cell_value(rowx=0, colx=0)
a1_as_datetime = datetime.datetime(*xlrd.xldate_as_tuple(a1, book.datemode))
print 'datetime: %s' % a1_as_datetime

如果创建文件myexcelfile.xls并在单元格A1中输入日期并运行上面的代码，则应该能够在a1_as_datetime变量中看到正确的日期时间值。

Python：来自奇怪时间戳记的日期转换

1 个答案: